La cadena de opciones muestra datos clave de las opciones de acciones de My City Builders a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para My City Builders..

My City Builders (OTC:MYCB) Bolsa, Cadena de Opciones

My City Builders Inc with its subsidiary focuses on real estate transactions, in which it buys and develops real estate for sale or rent of low-income housing. It also plans to invest in three sectors of the market by buying, refurbishing, and selling traditional foreclosures, buying, developing, and renting Land Banks that have an average pool of homes or lots, and buying, refurbishing, or developing and selling homes made available by the government through HECM pools.

MY CITY BUILDERS INC by My City Builders, Inc.

My City Builders Inc

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161-
-This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160-
NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,&nbsp;today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan.
Depending on the individual's deductible and out-of-pocket costs, these claims may not result in an immediate PoNS Device sale.

News

HSDT

Helius Medical Technologies Announces Additional Authorized Claim For Payment For PoNS Device From CignaHealth

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
—Patients report improved quality of life and daily functioning with ORLADEYO—

BCRX

BioCryst Reports Sustained Benefits Of Berotralstat in Children, Adolescents, And Adults With Hereditary Angioedema

Kirkland&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/KIRK/earnings">bell on Tuesday, June 17</a>.
Analysts expect the Brentwood, Tennessee-based company to report quarterly loss at 47 cents per share, versus a year-ago loss of 65 cents per share. Kirkland&#8217;s projects quarterly revenue of $85.56 million, compared to $91.75 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 1, Kirkland's reported disappointing fourth-quarter 2024 results and warned of substantial doubt over its ability to continue as a going concern.
Kirkland&#8217;s shares fell 4.8% to close at $1.19 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/KIRK/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Benchmark analyst John Lawrence reiterated a Buy rating with a price target of $7 on Oct. 23, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Craig-Hallum analyst Jeremy Hamblin maintained a Hold rating and lowered the price target from $2.5 to $2 on Sept. 6, 2024. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying KIRK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/KIRK/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-1024x589.png" alt="" class="wp-image-950578" style="width:704px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

KIRK

Kirkland's Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company) presented data in a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, held June 11-14, 2025, in Barcelona, Spain. A copy of the Company's poster, titled "Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Non-restorative Sleep and Provides Sustained Pain Reduction" is available under the <a href="https://www.globenewswire.com/Tracker?data=MBp6l1yE0UYuANFRaHcakT0YpPLwFdMkVv-sG5Z_BvnjCtvkoXNw7HPbhK1-zdW4JM1EJ2PYcf93TvQj_jWARwKm4AcWfMIGm6k0D9E8TBDogMAvA-Ed6lx7yGcevp8aCLRndB_H7jzMldmlI6vXVA==">Scientific Presentations</a> tab of the Tonix website at <a href="https://www.globenewswire.com/Tracker?data=mGj3zEWAkLkG6yt-vdOMKrNKcn4d98neV0wPM7Qwclwxuv_s5u9qn_RLBKTfU7dN12xCDJuWSLwAyNgezDAcmKLcaKhduNktLFfrz5YzCqE=">www.tonixpharma.com</a>. TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic designed for daily bedtime dosing with an FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025.

TNXP

Tonix Showcases New Fibromyalgia Drug That Targets Sleep and Pain Without Opioids

GTF maintenance agreement supports airline's long-term fleet plans
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, and Cebu Pacific (CEB) have signed a long-term EngineWise&#x2122; comprehensive maintenance services agreement for the airline's GTF engine fleet. This agreement aligns Cebu Pacific's maintenance costs to the utilization of the airline's engines.
Currently, Cebu Pacific operates 56 Pratt &amp; Whitney powered aircraft. Prior to GTF engines, Pratt &amp; Whitney supplied JT8D engines for the airline's DC-9 aircraft fleet. Pratt &amp; Whitney and Cebu Pacific's relationship extends back to the 1990s.

RTX's Pratt & Whitney And Cebu Pacific Signs Long-Term EngineWise Comprehensive Maintenance Services Agreement For Airline's GTF Engine Fleet

Biotech

Health Care

General

OCGN

The FDA Clears Ocugen's Investigational New Drug Amendment To Initiate A Phase 2/3 Pivotal Confirmatory Trial Of OCU410ST, A Modifier Gene Therapy Candidate For All Stargardt Disease (ABCA-associated Retinopathies)

Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulmonary diseases and a <a href="https://www.globenewswire.com/Tracker?data=DpTIhaLdQLBte6PaVAS9H8dtbui0nzNvQvcgSeW3t9MPo7q9aXjeqGhMPmyY7008U_mXZZd2TzkLujYw8zh01w==">Roivant</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) company, today announced the publication of Phase 1 pharmacokinetics (PK) in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension (PH). The peer-reviewed manuscript titled, "Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men," was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients.

ROIV

Pulmovant Unveils Phase 1 Results for Inhaled Drug Aiming to Treat Pulmonary Hypertension

TJ150 turbojet engines will power the multi-use Black Arrow missile&nbsp;
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, has secured a contract from Dynetics, a Leidos company, to supply TJ150 engines to be integrated with their Small Cruise Missile, known as Black Arrow.
Although preliminary integration studies with Pratt &amp; Whitney commenced in 2023, work under this current contract began in April 2025 and will run through the first quarter of 2026. There is an option to provide follow-on quantities of engines. The TJ150 is in production today, and Pratt &amp; Whitney is continuing to improve upon the engine with a focus on affordability.

RTX's Pratt & Whitney Secures Contract From Dynetics To Supply TJ150 Engines To Be Integrated With Small Cruise Missile, Known As Black Arrow

OCUL

Ocular Therapeutix To Highlight Advancements In Sustained-Release Axitinib Hydrogel For Retinal Disease At CTS 2025

VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) ("VivoPower") announced today that it has engaged advisors to fast-track execution in relation to its previously announced plan to directly spin off Caret LLC ("Caret Digital") through an IPO on NASDAQ.
&nbsp;
Caret Digital's strategy will be focused on digital asset mining, with an emphasis on mining DOGE as previously announced. With the first six-month phase of mining DOGE nearing successful completion, VivoPower is confident of the scalability of the business. Leveraging DOGE mining economics, Caret Digital will convert mined DOGE into either XRP or BTC, securing both at an effective discount (based on current DOGE mining economics), which will then allow it to execute on strategies to optimise yield and returns.
The implied market capitalisation for the spin-off is US$308 million (subject to change based on market conditions and other factors). Additionally, Caret Digital intends to raise up to US$50 million from strategic investors as part of the transaction to support growth plans and it has been engaged in negotiations with counterparties in the Middle East and Asia. Since the election of US President Donald Trump and the recent investment of the Trump brothers in digital asset mining, there has been a significant increase in interest in digital asset mining activities outside of the United States, including in countries where such activity has previously been prohibited. In addition, renewable power sources at sub 3c/watt have been identified.

IPOs

VVPR

VivoPower Fast-Tracks $308M Spin-Off of Crypto Unit Caret Digital Amid Global Mining Boom

<ul>
<li>Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications.</li>
<li>In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks, regardless of long-term prophylaxis mechanism of action</li>
</ul>

KALV

KalVista Pharmaceuticals Announced The Presentation Of New Data At The European Academy Of Allergy And Clinical Immunology Congress 2025

American Express Unveils Largest-Ever Platinum Card Refresh With Expanded Travel, Dining, And Business Perks

Approval advances transaction that will create America's leading reliable and clean energy provider, with coast-to-coast presence
Constellation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) today announced it has received regulatory approval from the New York State Public Service Commission (PSC) for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.constellationenergy.com%2Fnewsroom%2F2025%2Fconstellation-to-acquire-calpine-creates-americas-leading-producer-of-clean-and-reliable-energy-to-meet-growing-demand-for-customers-and-communities.html&amp;esheet=54273602&amp;newsitemid=20250612288071&amp;lan=en-US&amp;anchor=previously+announced&amp;index=1&amp;md5=fa14a2fe8096a883d1ad46429eaf16b5">previously announced</a> acquisition of Calpine Corporation.
The approval represents the most recent key step forward in Constellation's plans to combine the nation's largest zero-emissions nuclear fleet with Calpine's premier portfolio of low-emission natural gas and geothermal assets. The deal will establish a coast-to-coast platform capable of supporting growing demand for around-the-clock, sustainable power.

Constellation Receives Regulatory Approval From New York State PSC For Its Previously Announced Acquisition Of Calpine Corp.

<ul>
<li>iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody</li>
<li>New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition</li>
<li>Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%&#x2A;, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd</li>
</ul>

IBIO

iBio Initiates Non-human Primate Study For Its Activin E Engineered Antibody Candidate, Now Named IBIO-610. This Preclinical Study Will Evaluate The Pharmacokinetics And Early Signs Of Efficacy Of IBIO-610 In Obese And Elderly NHPs, Including Its Impact On Fat And Body Composition

NXTC

NextCure Announced Strategic Partnership With Simcere Zaiming To Develop SIM0505, a CDH6-Targeting Antibody-Drug Conjugate for Solid Tumors

<ul>
<li>New Toyota&nbsp;Prius Plug-in&nbsp;Hybrid Nightshade Edition Available in 2026</li>
<li>Available in&nbsp;Karashi, Wind Chill Pearl, and Midnight Black Metallic</li>
<li>Up to 44-Miles of Manufacturer-Estimated All Electric Driving Range Rating&nbsp;</li>
<li>Up to a Manufacturer-Estimated 52 Combined MPG Rating in Hybrid Mode&nbsp;</li>
<li>Standard Toyota Audio Multimedia and Toyota Safety Sense 3.0</li>
</ul>
PLANO, Texas, June 16, 2025 /PRNewswire/ -- For 2026, Toyota is introducing the Prius Plug-in&nbsp;Hybrid Nightshade Edition – a bold new chapter in the Prius lineup that fuses sleek sophistication with an unmistakable edge. Built off the XSE grade, the Nightshade Edition elevates the iconic design with an array of captivating black accents that enhance the already stunning profile. From the sleek black badging and door sills to the stylish door handles and bumper trim, every detail has been meticulously crafted to create a cohesive and aggressive look.
The 2026 Prius Plug-in Hybrid is expected to arrive at Toyota dealerships this summer. The Manufacturer's Suggested Retail Price, excluding Dealer Processing and Handling, will start at $33,775 for the SE grade.&nbsp;
 &nbsp;

Toyota Introduces Prius Plug-In Hybrid Nightshade Edition For 2026

If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.

AQST

The FDA Has Accepts Aquestive Therapeutics' New Drug Application For Anaphylm For Type 1 Allergic Reactions, Including Anaphylaxis, With PDUFA Target Action Date Of January 31, 2026

Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>, the ", Company", ))), a provider of innovative smart cloud platform services and solutions, today announced that on June 13, 2025, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has cured its bid price deficiency, and that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). Accordingly, this matter is now closed and the Company's ordinary shares will continue to trade uninterrupted on Nasdaq under the ticker "TAOP".

TAOP

Taoping Regains Nasdaq Compliance, Stock To Trade Uninterrupted

On Friday, June 13, U.S. markets ended sharply lower as escalating Iran-Israel tensions rattled global markets. Oil prices jumped on fears of supply disruption, boosting energy and defense stocks, while airlines tumbled on rising fuel concerns.
Most sectors in the S&amp;P 500 declined, led by financials and tech. Despite positive consumer sentiment and stable inflation data, geopolitical risks weighed heavily on investor confidence and market performance.
According to economic data, the University of Michigan&#8217;s consumer sentiment index rose to 60.5 in June, up from 52.2 in the prior two months and above expectations of 53.5.
While most S&amp;P 500 sectors, including financials, tech, and materials, posted losses Friday, energy stocks closed higher against the trend. The Dow closed lower by 1.79% at 42,197.79, the S&amp;P 500 declined 1.13% to 5,976.97, and the Nasdaq slipped 1.30% to 19,406.83.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/macro-economic-events/25/06/45943707/us-economy-to-face-pretty-limited-impact-from-israel-iran-airstrikes-with-only-a-tiny-bit-recession-risk-say-economists" rel="noreferrer noopener">US Economy To Face &#8216;Pretty Limited&#8217; Impact From Israel-Iran Airstrikes, With Only A &#8216;Tiny Bit&#8217; Recession Risk, Say Economists</a>
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Monday, Japan&#8217;s Nikkei 225 closed 1.29% higher at 38,324.00, led by gains in the Real Estate, Banking, and Textile sectors.
Australia&#8217;s S&amp;P/ASX 200 was up 0.01% at 8,548.40, led by gains in the Energy, IT and Telecoms Services sectors.
India&#8217;s Nifty 50 was up 0.89% at 24,937.40, and the Nifty 500 gained 0.79% to 23,086.95.
China&#8217;s Shanghai Composite was up 0.35% at 3,388.73, and Shanghai Shenzhen CSI 300 rose 0.25% to 3,873.80.
Hong Kong&#8217;s Hang Seng closed the session 0.70% higher at 24,060.9
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was up 0.42%.
Germany&#8217;s DAX index gained 0.32%.
France&#8217;s CAC 40 rose 0.71%.
U.K.&#8217;s FTSE 100 index traded higher by 0.38%.
<h2 class="wp-block-heading">Commodities at 05:45 AM ET</h2>
Crude Oil WTI was trading lower by 0.60% at $70.86/bbl, and Brent was down 0.73% at $73.74/bbl.
Oil prices dipped Monday after a sharp surge on Friday, as Israeli-Iranian strikes over the weekend left oil facilities intact. Brent and WTI futures gave back earlier gains despite briefly rising over $4 in Asian trading.
Natural gas rose 2.90% to $3.685.
Gold traded lower by 0.61% to $3,431.70, Silver rose 0.10% to $36.393, and Copper fell 0.28% to $4.8008.
<h2 class="wp-block-heading">U.S. Futures</h2>
At 05:45 AM ET, the Dow Jones futures rose 0.36%, the S&amp;P 500 gained 0.41%, and Nasdaq 100 was up 0.49%.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index declined 0.24% to 97.98, USD/JPY was up 0.01% to 144.12, and USD/AUD declined 0.42% to 1.5348.
The dollar held steady Monday amid Israel-Iran tensions and ahead of key central bank meetings, while risk currencies edged higher and oil prices eased from last week&#8217;s surge.
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Rise, Dollar Slips Ahead Of Central Bank Decisions - Global Markets Today While US Slept

Highlights:
<ul>
<li>Over $11 Million Raised:&nbsp;Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant exercises.</li>
<li>Update on NASDAQ Compliance:&nbsp;Klotho believes it now exceeds the stockholders' equity thresholds required to remain in compliance with NASDAQ listing requirements.</li>
<li>Zero Debt:&nbsp;Klotho has fully extinguished all outstanding debt, resulting in a debt-free balance sheet.</li>
</ul>
NEW YORK, June 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq's stockholders' equity requirement requirements outlined in its Nasdaq compliance plan.

Comments

My City Builders

My City Builders (MYCB) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL